reason report
long-term outlook still lever pop-seq growth despit
bottom line remain op view
major popul develop emerg world
like touch one genet test lifetim
creat massiv market benefit report
quarter recent pre-announc miss
vs street us lower full-year revenu guid
maintain full yr guid provid insight
quarter major pop-seq order move microarray
servic dtc declin given uncertainti associ exact
time pop-seq project believ go maintain
conserv guid also lower revenu growth though
acknowledg time challeng see guid still
conserv pop-seq market bound drive growth
outlook lever pop-seq growth longer term despit
lower expect pop-seq project includ us
genom pilot nh commiss genom view
still see upsid uk biobank longitudin pop-seq studi
genom yr ramp soon project fund
expect august per medacorp specialist link recal
genom lead pop-seq project hold potenti
deliv revenu genom
run within year still de-risk entir pop-seq
revenu take major pop-seq revenu see
dtc busi recoveri uncertain believ nextseq user
continu shift toward novaseq microarray servic dtc
busi declin microarray consum growth
declin well will call recoveri
dtc market see market still highli under-penetrated
microarray estim lower entir year
ultim believ market shift reach
genom nextseq weak cite earlier acut
benchtop platform continu grow nextseq dx grew strongli
guid remain conserv view believ full
year top-lin growth guid remain conserv given shift
sizabl pop-seq project move pop-seq check
suggest upsid link still strong oncolog market
overal much easier compar setup growth lower
price per gb drive expans sequenc market model
organ growth lead revenu estim
larg unchang ep move lower
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud charg amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target believ
major popul develop emerg world like touch one
genet test lifetim creat massiv market believ stand
benefit market compani see sequenc market
number sampl depth coverag expand dramat next year
novaseq upcom instrument drive signific reduct sequenc cost
earlier hiseq current novaseq flow cell like
futur set path genom price beyond high throughput
platform also continu drive double-digit growth desktop system includ nextseq
essenti key high growth market includ non-invas pre-nat test nipt
faster turn-around sampl oncolog continu domin sequenc
market world-wide life scienc genet test reproduct health oncolog
market share revenu market share sequenc unit believ ilmn
market share accuraci throughput enterpris level servic product factor
continu keep custom bound despit custom consid higher
price still direct strong competit sight somewhat unbound market
believ continu domin next-gen sequenc keep drive sequenc cost
lower lead elast demand sampl deeper sequenc need
share current trade price-to-earnings consensu ep
multipl view potenti unbound market opportun
major popul develop develop world touch sequenc
form test next year use dcf analysi beta long-
term growth rate wacc arriv price target believ
remain strong forc sequenc market see revenu growth continu
outer year addit believ long-term growth rate conserv
estim given sequenc repres somewhat unbound market opportun
view still applic continu explor beyond current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given near-monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
slightli vs
improv bp
slightli higher
improv bp
gener in-lin
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report svb leerink estim
 depreci alreadi ex amort
